Trials / Completed
CompletedNCT00279721
Phase II Study of IMRT With SIB as Adjuvant Treatment for High Risk Resected Well-differentiated Thyroid Cancer.
Phase II Study of Intensity-modulated Radiation (IMRT)With Simultaneous Integrated Boost (SIB) as Adjuvant Treatment for High Risk Resected Well-differentiated Thyroid Cancer.
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- Sponsor
- Alberta Health services · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Resected well-differentiated thyroid neoplasms with at least one high risk feature will receive adjuvant radiation using IMRT with SIB. The acute toxicity and locoregional control rate at 2 years will be recorded.
Detailed description
Resected well-differentiated thyroid neoplasms with at least one high risk feature will receive adjuvant radiation using IMRT with SIB. The acute toxicity and locoregional control rate at 2 years will be recorded.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | IMRT |
Timeline
- Start date
- 2006-01-01
- Primary completion
- 2010-06-01
- Completion
- 2010-06-01
- First posted
- 2006-01-20
- Last updated
- 2012-01-19
Source: ClinicalTrials.gov record NCT00279721. Inclusion in this directory is not an endorsement.